Posts Tagged ‘obesity complications’

FDA Approves Resmetirom: First Ever for MASH with Fibrosis

March 16, 2024 — Firsts are worth celebrating. In this case, the cause for celebration is especially great. MASH or metabolic steatohepatitis is a disease that is growing dramatically more common and more harmful to the health of the population. Late this week, FDA approved resmetirom to be the first ever treatment for MASH with fibrosis. Note that the […]

Progress Reported in MASH with Survodutide

February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]

Possible Benefits for Brain Function from Obesity Treatment

February 20, 2024 — The potential for benefits to brain function with effective obesity treatment is becoming difficult to miss. In particular, a new observational study of brain function in a cohort of patients receiving metabolic surgery for treatment of obesity is drawing much attention right now in JAMA Network Open. It suggests the possibility of a lasting benefit […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

New Data on Obesity and Cancer in Young Persons

January 18, 2024 — Cancer is rising in young persons and it appears that obesity is playing a role. Of course, this is not to say that obesity tells the whole story. Cancer prevalence patterns present a complex puzzle – just as obesity prevalence does. A Continuing Shift Toward Younger Persons Yesterday in CA: A Cancer Journal for Clinicians, […]

Impressive Semaglutide Outcomes in Obesity and Heart Failure

August 26, 2023 — Scientists who study semaglutide in obesity are producing a steady stream of impressive results. Yesterday in the New England Journal of Medicine, a randomized controlled trial in persons with obesity and heart failure with preserved ejection fraction demonstrated superior weight reduction, improvement in heart failure, better physical functioning, and a halving of serious adverse events. […]

Pricing Childhood Obesity While Discounting the Future

July 4, 2023 — JAMA Pediatrics has a pair of new papers today on the cost of childhood obesity. One of them adds up the medical expenses incurred by youth aged 2 to 19. The other editorializes about determining the value of interventions to manage weight. Both of them focus on pricing childhood obesity in the present while discounting […]

Sleep Apnea, Metabolic Surgery, and the Risk of Death

June 30, 2023 — At the ASMBS Annual Meeting this week, a new study of major bad outcomes in people with both obesity and sleep apnea reminds us why metabolic surgery remains an important option for comprehensive obesity care. The risk of death, heart attacks, strokes, and other major bad cardiovascular outcomes is 37 percent lower if a person […]

Preventing Long COVID for People with Obesity

June 12, 2023 — In many ways, COVID seems to be in the rear view mirror. Travel, meetings, and busyness have cranked up to a level that makes it seem like the pause we took for the pandemic is a distant memory. But not for folks who develop long COVID – which is about ten percent of people who […]

The Mental Health Burden of Obesity for Women

June 1, 2023 — New research provides impressive evidence for the contribution of obesity to the risk of a range of mental health disorders. These include depression, psychosis, eating and personality disorders. The added risk is apparent at all ages, in both men and women. Furthermore, these data suggest that the mental health burden of obesity is greater in […]